Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT04906395 is registered in ClinicalTrials.gov with Tolmar Inc. as lead sponsor.

NCT NCT04906395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04906395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Lead sponsor
Tolmar Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 1, 2021
Completion date
November 30, 2026
Enrollment
250 (estimated)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer